Acrivon Therapeutics, Inc. (ACRV) — 8-K Filings

8-K Filings (15)

• 8-K Filing — Sep 5, 2025
• Acrivon Therapeutics Files 8-K — Aug 13, 2025 Risk: low
  Acrivon Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and
• Acrivon Therapeutics Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
  Acrivon Therapeutics, Inc. filed an 8-K on June 13, 2025, to report on matters submitted to a vote of its security holders. The filing does not disclose specifi
• Acrivon Therapeutics Files 8-K — Apr 7, 2025 Risk: low
  Acrivon Therapeutics, Inc. filed an 8-K on April 7, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
• Acrivon Therapeutics Files 8-K on Financials and Operations — Mar 25, 2025 Risk: low
  On March 25, 2025, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, al
• Acrivon Therapeutics Reports Officer/Director Changes & Compensation — Mar 14, 2025 Risk: medium
  Acrivon Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on events as of March 11, 2025. The filing primarily concerns the departure of directors or
• Acrivon Therapeutics Files 8-K Report — Oct 11, 2024 Risk: low
  On October 11, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events an
• Acrivon Therapeutics Files 8-K — Sep 16, 2024 Risk: low
  On September 14, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events
• Acrivon Therapeutics Files 8-K on Security Holder Vote — Jun 21, 2024 Risk: low
  On June 20, 2024, Acrivon Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The company, incorporated in
• Acrivon Therapeutics Files 8-K on Financials — May 14, 2024 Risk: low
  Acrivon Therapeutics, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statement
• Acrivon Therapeutics Files 8-K on Financials and Operations — Apr 24, 2024 Risk: medium
  On April 24, 2024, Acrivon Therapeutics, Inc. filed an 8-K report. The filing primarily concerns results of operations and financial condition, Regulation FD di
• Acrivon Therapeutics Announces Material Definitive Agreement — Apr 9, 2024 Risk: medium
  Acrivon Therapeutics, Inc. announced on April 8, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of eq
• Acrivon Therapeutics Files 8-K on Director Changes and Compensation — Mar 4, 2024 Risk: low
  On March 4, 2024, Acrivon Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Acrivon Therapeutics Reports Officer/Director Changes, Comp Arrangements — Feb 8, 2024 Risk: medium
  Acrivon Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an event that occurred on February 7, 2024, related to changes in its directors or office
• Acrivon Therapeutics Confirms Emerging Growth Company Status — Jan 8, 2024
  Acrivon Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose that it is an emerging growth company, as defined by the Securities Act of 1933 and the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX